Navigation Links
Access Pharmaceuticals Raises $6.0 Million In Registered Direct Offering
Date:12/10/2010

DALLAS and NEW YORK, Dec. 10, 2010 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has entered into definitive agreements with existing and new accredited investors to sell, in a registered direct offering, an aggregate of approximately 2.3 million shares of its common stock at a price of $2.55 per share for aggregate gross proceeds of $6.0 million.  Additionally, at the closing, Access will issue to the investors warrants to purchase, in the aggregate, approximately 0.7 million shares of common stock at a price of $3.06 per share, which warrants are exercisable immediately for a term of 5 years from the closing date.  The initial closing of the offering is expected to take place subject to the satisfaction of customary closing conditions.

"In addition to providing Access capital to support the commercial launch of MuGard, this financing should prove to be a positive for Access investors as it also helps shore up our balance sheet for partnering discussions in our various programs," stated Jeffrey B. Davis, President & CEO.  He continued, "This additional funding from current and new investors will provide a strong foundation to continue executing on our multifaceted strategy for moving valuable assets within the company forward."

Hudson Securities, Inc., a subsidiary of Hudson Holding Corporation (OTC Bulletin Board: HDHL), acted as the Company's placement agent in connection with the offering. The common stock and warrants are being offered by Access pursuant to an effective registration statement(s) on Form S-1 filed with the Securities and Exchange Commission ("SEC").

This press rele
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cellectis bioresearch Signs Non-Exclusive License With Evrogen for Access to Fluorescent Proteins
2. ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program
3. Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology
4. Dynamic Ventures Corporations Information To Be Available Through Standard & Poors Market Access Program
5. Castle Access Names New Managing Director
6. Full Agenda Announced for CBIs Commercialization and Market Access Congress (CMAC 2010)
7. Access Pharmaceuticals Furthers Progress on Its Cobalamin-mediated Targeted Drug Delivery Platform for siRNA
8. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
9. Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
10. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
11. Orchestrall Sponsors China Business Toolbox: Brings Focus to the How and When of China Market Access
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... MARLBOROUGH, Mass. , Aug. 31, 2015 /PRNewswire/ ... biotechnology company focused on discovering and developing innovative ... ophthalmology, today announced that the 30-day review period ... Drug (IND) for ocular indications with the U.S. ... the IND is now active. ...
(Date:8/31/2015)... , Aug. 31, 2015 Trimb Healthcare AB ... to acquire YouMedical Group BV ("YouMedical"), a Dutch OTC ... total annual sales of approximately EUR 16 million, with ... "Our ambition is to build a leading ... step toward that goal. YouMedical gives us a stronger ...
(Date:8/30/2015)... , August 31, 2015 , ... Frau   für chirurgische   Behandlung     ... 7-90   werden für eine   verheerende   Geburtsverletzung ... behandeln und die Anzahl ausgebildeter Chirurgen in Kenia bis ... gab heute bekannt, dass  Action on Fistula  seit ihrem ...
(Date:8/28/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, ... June 30, 2015, corporate highlights, and near-term milestones.  ... available at www.sedar.com ,  www.edgar.com ... "RepliCel expects to launch its RCS-01 treatment for ...
Breaking Biology Technology:RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5
... Event Underscores Commitment to Diverse Workforce, OAKLAND, ... diversity in the workplace, Kaiser Permanente today opened,its ... This year,s conference will focus on Kaiser ... integrate diversity into every,aspect of daily business operations. ...
... RICHMOND, Va., Dec. 12 Insmed Inc. (Nasdaq:,INSM), ... grant of $2,087,325 from,the Muscular Dystrophy Association (MDA). ... of the external costs associated with Insmed,s 24-week,Phase ... Dystrophy (MMD)., Insmed, a development stage biopharmaceutical ...
... An IND has Been Filed With the FDA for ... Developed Under the Company,s Collaboration with Roche., ... today that an Investigational New Drug application (IND) for ... has,been filed with the FDA by Roche. Genentech and ...
Cached Biology Technology:Kaiser Permanente to Host 30th Annual Diversity Conference 2Kaiser Permanente to Host 30th Annual Diversity Conference 3Insmed Awarded $2.1 Million by Muscular Dystrophy Association 2Insmed Awarded $2.1 Million by Muscular Dystrophy Association 3Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 3
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
(Date:8/4/2015)... 2015  AMRI (NASDAQ: AMRI ) today reported financial and ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 % ... a $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial ...
(Date:7/31/2015)... de julho de 2015 A 10 a. ... será realizada pela BGI de 22-25 de outubro de 2015, ... A conferência está celebrando seu 10 o. aniversário ... se tornou uma das reuniões mais influentes do mundo ... mais dinâmicos, entusiastas e prazerosos. A ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... origami", the way that proteins fold is vital to ... of Leeds have discovered this is a ,hit and ... before they form the correct structure for their intended ... functions and play a crucial role in the growth, ...
... of a previously unknown protein in the cells of ... diagnosis of a serious lung disease. The findings, ... journal Proceedings of the National Academy of Sciences ... of common diseases like asthma and chronic bronchitis. ...
... levels of vitamin B12 shortly before and after conception may ... to an analysis by researchers at the National Institutes of ... Ireland. Women with the lowest B12 levels had 5 ... tube defect compared to women with the highest B12 levels. ...
Cached Biology News:Unfolding 'nature's origami' 2Low levels of vitamin B12 may increase risk for neural tube defects 2Low levels of vitamin B12 may increase risk for neural tube defects 3Low levels of vitamin B12 may increase risk for neural tube defects 4
... covers can be used with ... covers for stacking of covered ... for use with automated systems ... and non-ridged, are available for ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ID ...
... Ion Chromatography requirements, IonQuest will ... The newly developed conductivity detector ... exceptionally ultra-low drift . The ... creates even higher sensitivities for ...
... An excellent ion chromatography system . ... ranges from 0.01S to 5000S, houses the measuring ... module CE 4715, is available. Data processing ... software., Solvent delivery is by the high pressure ...
Biology Products: